USS Investment Management Ltd lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 1.7% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 222,215 shares of the biopharmaceutical company’s stock after selling 3,736 shares during the quarter. USS Investment Management Ltd’s holdings in Gilead Sciences were worth $33,120,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Westpac Banking Corp lifted its holdings in shares of Gilead Sciences by 3.6% during the 3rd quarter. Westpac Banking Corp now owns 81,263 shares of the biopharmaceutical company’s stock valued at $12,112,000 after acquiring an additional 2,798 shares in the last quarter. Private Advisor Group LLC boosted its position in Gilead Sciences by 44.4% during the 3rd quarter. Private Advisor Group LLC now owns 63,196 shares of the biopharmaceutical company’s stock worth $9,419,000 after purchasing an additional 19,437 shares during the period. Ieq Capital LLC boosted its position in Gilead Sciences by 375.7% during the 3rd quarter. Ieq Capital LLC now owns 160,503 shares of the biopharmaceutical company’s stock worth $23,923,000 after purchasing an additional 126,764 shares during the period. Focus Advisor Solutions LLC acquired a new stake in Gilead Sciences in the 3rd quarter valued at $2,619,000. Finally, Checchi Capital Advisers LLC increased its holdings in Gilead Sciences by 5.4% in the 3rd quarter. Checchi Capital Advisers LLC now owns 10,372 shares of the biopharmaceutical company’s stock valued at $1,546,000 after purchasing an additional 533 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.
Analyst Upgrades and Downgrades
Several research analysts have commented on GILD shares. Morgan Stanley raised their price objective on Gilead Sciences from $163.00 to $183.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. JPMorgan Chase & Co. upped their target price on Gilead Sciences from $170.00 to $190.00 and gave the stock an “overweight” rating in a research report on Friday, October 30th. Jefferies Financial Group set a $196.00 target price on Gilead Sciences in a research note on Wednesday, November 4th. UBS Group raised their target price on Gilead Sciences from $175.00 to $195.00 and gave the company a “buy” rating in a report on Friday, October 30th. Finally, Bank of America boosted their price target on Gilead Sciences from $168.00 to $172.00 and gave the stock a “buy” rating in a research report on Tuesday, October 20th. Twenty-three equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $171.63.
View Our Latest Analysis on Gilead Sciences
Gilead Sciences Price Performance
GILD opened at $166.53 on Friday. Gilead Sciences, Inc. has a twelve month low of $116.88 and a twelve month high of $176.58. The firm has a market cap of $206.55 billion, a price-to-earnings ratio of -52.70 and a beta of 0.35. The company has a current ratio of 1.38, a quick ratio of 1.22 and a debt-to-equity ratio of 1.84. The company has a fifty day simple moving average of $156.80 and a 200 day simple moving average of $142.34.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, topping analysts’ consensus estimates of $2.19 by $0.36. The firm had revenue of $8.30 billion for the quarter, compared to analyst estimates of $7.81 billion. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The firm’s revenue was up 6.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.47 EPS. Equities research analysts expect that Gilead Sciences, Inc. will post -0.97 EPS for the current fiscal year.
Gilead Sciences Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be given a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date of this dividend is Tuesday, December 15th. Gilead Sciences’s payout ratio is presently -103.80%.
Insiders Place Their Bets
In related news, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction dated Monday, November 16th. The stock was sold at an average price of $170.55, for a total value of $4,775,400.00. Following the transaction, the insider owned 110,684 shares in the company, valued at approximately $18,877,156.20. The trade was a 20.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Dickinson sold 3,000 shares of the stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $171.47, for a total value of $514,410.00. Following the completion of the transaction, the chief financial officer directly owned 158,096 shares of the company’s stock, valued at $27,108,721.12. This represents a 1.86% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 237,709 shares of company stock valued at $39,799,137 in the last three months. 0.30% of the stock is owned by insiders.
Gilead Sciences Company Profile
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.
Further Reading
- Five stocks we like better than Gilead Sciences
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
